Xilio Therapeutics, Inc. (NASDAQ:XLO) has 37 institutional investors that have filed 13F reports for the period ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 31 Dec, 2025 | 9,105,451 | 0 | 0.00% | $5,829,310.00 |
| Bain Capital Life Sciences Investors, LLC | 31 Dec, 2025 | 7,372,686 | 2,805,869 | 61.44% | $4,719,994.00 |
| Frazier Life Sciences Management, L.P. | 31 Dec, 2025 | 5,915,091 | 5,915,091 | 0.00% | $3,786,841.00 |
| Point72 Asset Management, L.P. | 31 Dec, 2025 | 4,000,000 | 4,000,000 | 0.00% | $2,560,800.00 |
| Sio Capital Management, LLC | 31 Dec, 2025 | 2,134,537 | 2,134,537 | 0.00% | $1,366,531.00 |
| STEMPOINT CAPITAL LP | 31 Dec, 2025 | 2,030,028 | 2,030,028 | 0.00% | $1,299,624.00 |
| Merck & Co., Inc. | 31 Dec, 2025 | 1,483,758 | 0 | 0.00% | $949,902.00 |
| VANGUARD GROUP INC | 31 Dec, 2025 | 1,255,692 | 0 | 0.00% | $803,643.00 |
| Empery Asset Management, LP | 31 Dec, 2025 | 1,183,040 | 1,183,040 | 0.00% | $757,382.00 |
| Ghisallo Capital Management LLC | 31 Dec, 2025 | 1,113,222 | 1,113,222 | 0.00% | $712,685.00 |
| Morgan Stanley | 31 Dec, 2025 | 839,850 | -122,067 | -12.69% | $537,672.00 |
| AJU IB Investment Co., Ltd. | 31 Dec, 2025 | 667,742 | 0 | 0.00% | $427,488.00 |
| FMR LLC | 31 Dec, 2025 | 511,820 | 0 | 0.00% | $327,667.00 |
| CITADEL ADVISORS LLC | 31 Dec, 2025 | 436,216 | 436,216 | 0.00% | $279,265.00 |
| RENAISSANCE TECHNOLOGIES LLC | 31 Dec, 2025 | 344,416 | 139,716 | 68.25% | $220,495.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Dec, 2025 | 328,972 | 0 | 0.00% | $210,630.00 |
| State Street Corp | 31 Dec, 2025 | 186,390 | 22,500 | 13.73% | $119,327.00 |
| Velan Capital Investment Management LP | 31 Dec, 2025 | 170,000 | 170,000 | 0.00% | $108,834.00 |
| GSA CAPITAL PARTNERS LLP | 31 Dec, 2025 | 147,966 | 147,966 | 0.00% | $95.00 |
| Stonepine Capital Management, LLC | 31 Dec, 2025 | 126,270 | 126,270 | 0.00% | $80,838.00 |